Revance Therapeutics, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Investigation Details

On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it “received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company’s exclusive distribution agreement with Teoxane SA”. Due to the dispute with Teoxane, Revance advised that the previously announced tender offer by Crown Laboratories, Inc. had been delayed until at least October 4, 2024.

Following this news, Revance’s stock price fell over 7% on the same day.